KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) FCF Margin (2018 - 2026)

Moderna (MRNA) has disclosed FCF Margin for 9 consecutive years, with 170.95% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin rose 83553.0% year-over-year to 170.95%; the TTM value through Mar 2026 reached 73.84%, up 5668.0%, while the annual FY2025 figure was 106.22%, 1908.0% up from the prior year.
  • FCF Margin hit 170.95% in Q1 2026 for Moderna, down from 115.04% in the prior quarter.
  • Across five years, FCF Margin topped out at 115.04% in Q4 2025 and bottomed at 1006.48% in Q1 2025.
  • Average FCF Margin over 5 years is 216.27%, with a median of 75.69% recorded in 2025.
  • Year-over-year, FCF Margin plummeted -57565bps in 2024 and then skyrocketed 83553bps in 2026.
  • Moderna's FCF Margin stood at 26.4% in 2022, then crashed by -92bps to 2.24% in 2023, then soared by 1300bps to 31.37% in 2024, then surged by 267bps to 115.04% in 2025, then plummeted by -249bps to 170.95% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 170.95%, 115.04%, and 75.69% for Q1 2026, Q4 2025, and Q3 2025 respectively.